Clinical trial · Interventional
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
NCT00911092CI-TRIAL-00005995COLcompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
| Chemotherapy (Fluorouracil and Cisplatin) | Drug | — | UNRESOLVED |
| Radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
- timeFrame
- 15 weeks after the end of irradiation
- measure
- Initial complete clinical response
- timeFrame
- 15 weeks after the end of irradiation
Secondary outcomes (1)
- measure
- Prolonged clinical response at one year
- timeFrame
- One year after the end of irradiation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven * Treated by exclusive concomitant radiochemotherapy * Written informed consent Exclusion Criteria: * Presence of a second uncontrolled cancer * Metastatic carcinoma * Metastatic disease, except cervical lymphnodes... (M1a) * In situ carcinoma * Eso-gastric junction cancer (Siewert II ou III) * Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
References
Publications (0)
Data not yet available
No reference posted for this study.